Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark

Abstract

Introduction:The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin has shown reductions in major adverse cardiac events similar to glucagon-like peptide-1 receptor agonists (GLP-1RAs). However, evidence is limited about how these therapies compare regarding overall healthcare resource utilization and costs in routine clinical care. Methods: We conducted a comparative cohort study based on linked prospective healthcare databases for the entire population of Denmark during 2015-2018. We included 13,747 new

Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia

“…The existing literature presents conflicting views on the cost-effectiveness of GLP-1 analogues compared to other hypoglycemic agents, largely due to variations in study methodology, choice of decision-analytical models, and potential sponsorship bias ( Laursen et al, 2023 ). Recent reviews and studies from other countries suggest that new hypoglycemic agents are cost-effective when added to metformin for managing uncontrolled T2DM, although SGLT2 inhibitors often emerge as the most economical option ( Zhu et al, 2023 , Chien et al, 2020 , Thomsen et al, 2022 , Wysham et al, 2018 , Poonawalla et al, 2021 ). Rose et al also noted a significant increase in the monthly cost of hypoglycemic agents after initiating GLP-1 analogues ( Rose et al, 2020 ).…”